# Efficacy and Safety of MEDI7352 in Participants With Painful Diabetic Neuropathy

> **NCT03755934** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 112 (actual)

## Conditions studied

- Painful Diabetic Neuropathy

## Interventions

- **DRUG:** MEDI7352
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03755934
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-19
- **Primary completion:** 2023-06-29
- **Final completion:** 2023-06-29
- **Target enrollment:** 112 (ACTUAL)
- **Why stopped:** The study was prematurely terminated due to longer enrolment time than was anticipated.
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03755934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03755934, "Efficacy and Safety of MEDI7352 in Participants With Painful Diabetic Neuropathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03755934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*